SGLT2i gives consistent CV benefit and tolerability in HF patients irrespective of diabetes3' education - Nov. 16, 2019 - John McMurray, Glasgow - AHA 2019, Philadelphia
This recording was independently developed under auspices of EPCCS. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of EPCCS.
Prof. John McMurray is Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, UK and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.
This video was recorded at the congress of the American Heart Association in Philadelphia, on November 16-18, 2019.